Please login to the form below

Not currently logged in
Email:
Password:

Trophos SA Awarded $1.4mn research grant

Agence Nationale pour la Recherche, the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development.

Agence Nationale pour la Recherche (ANR), the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development.

Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug TRO40303.

The research project, which is called IRIstop, is hoping to evaluate the ability of TRO40303 to curb cellular damage that occurs in cardiac and cerebral ischemia-reperfusion injury.

CEO at Trophos, Antoine Beret, said: "We are very pleased that the ANR has chosen to support the preclinical and clinical development of TRO40303 as a potential treatment for cardiac and cerebral ischemia-reperfusion injury."

Professor Alain Berdeaux of the University of Creteil's Institut Mondor de Recherche Biomedicale, and Professor Michael Plotkine of the Paris Descartes, Faculte de sciences pharmaceutiques et biologiques will be collaborating on project IRIstop.

Compounds contained within TRO40303 have been found to stimulate function and survival of neurons, cardiomyocytes, and hepatocytes.

Beret said: "This would be the second Trophos product to enter the clinic with a mitochondria-based mechanism of action that is predicted to exhibit a therapeutic benefit in diseases such as neuropathic pain, ischemia-reperfusion injury, and hepatotoxicity."

28th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics